CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 59 enrolled
Drug / intervention
Asparaginase +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00537030
NCT00537030N/ACompleted
CompareCT.gov

Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase?; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL)

Children's Oncology Group·interventional·Posted Sep 28, 2007·Updated Jul 9, 2019

In Brief

A clinical study evaluating Asparaginase, Laboratory Biomarker Analysis, and 1 other intervention for Adult Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia. Completed, enrolled 59 participants across 43 sites.

Detailed Summary

This clinical trial is studying the side effects of Erwinia asparaginase and what happens to the drug in the body in treating young patients with acute lymphoblastic leukemia who are allergic to PEG-asparaginase. Drugs used in chemotherapy, such as Erwinia asparaginase, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 28, 2007
Enrollment StartFeb 11, 2008
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 18.8 years ago

Interventions

Asparaginasedrug

Given IM

Laboratory Biomarker Analysisother

Correlative studies

Pharmacological Studyother

Correlative studies